FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029128617> ?p ?o ?g. }

• W3029128617 endingPage "527" @default.
• W3029128617 startingPage "523" @default.
• W3029128617 abstract "Objective To observe the clinical efficacy of mesalazine and bifid-triple viable combination therapy in patients with ulcerative colitis (UC).Methods Thirty-eight UC patients were evenly divided into mesalazine group and combination group. Patients in mesalazine group were administrated with mesalazine (1.0 g/time,four times/day),and on the basis of this,the patients in combination group were added into bifid-triple viable (420 mg/time,three times/day).The course of treatment was eight weeks.The improvement of patients' clinical symptom and manifestation under colonoscope were observed at second day after hospitalization and eight weeks after medication.Mayo disease activity index was used for scoring.Before and after the treatment,the expression of intestinal mucosa nuclear factor kappa B (NF-κB),tumor necrosis factor-α (TNF-a) and cyclooxygenase-2 (COX-2) were tested by immunohistochemical staining and the levels of serum TNF-α,interleukin-8 (IL-8), interleukin-10 (IL-10) were determined by double antibody sandwich enzyme-linked immunosorbent assay.The level of serum superoxide dismutase (SOD) and malondialdehyde (MDA) was detected by nitrite method and thiobarbituric acid coloration method.Before and after treatment was compared with paired t-test,and qualitative data was analyzed with ordinal rank sum test.Results Mayo disease activity index score of the combination group decreased from 7.16±2.01 to 1.63± 1.30 while the mesalazine group from 7.42 ± 1.95 to 3.00 ± 1.25.The difference of reduction was statistically significant (t =2.093,P =0.043).The efficiency of the combination group was higher than that of mesalazine group (16/19 vs 10/19,Fisher's exact test,P=0.039).After treatment,the expressions of NF-κB,TNF-α and COX-2 in colonic mucosa of two groups were both lower than those of before treatment,and in combination group the decrease were more significant (t value was 2.262,2.607 and 2.522 respectively,P value was 0.027,0.012 and 0.014 respectively).After treatment,the concentration of IL-8 of mesalazine group and the combination group both significantly decreased,however IL-10 significantly increased. The difference between these two groups was statistically significant (t value of TNF-α,IL-8 and IL-10 was 4.244,6.858 and 6.802 respectively,all P＜ 0.01). After treatment,both SOD vitality of two groups increased compare with that before treatment,however the level of MDA was lower than that before treatment and the changes of combination group were more significant.Conclusion The combination therapy with mesalazine and bifid-triple viable can effectively suppress inflammatory response in mild and moderate ulcerative colitis,and bifid-triple viable may play a role as adjuvant therapy for patients with UC.Key words: Colitis, ulcerative;  Cytokines;  Reactive oxygen species;  Mesalamine;  Bifidobacterium ;  Probiotics" @default.
• W3029128617 created "2020-06-05" @default.
• W3029128617 creator A5016101082 @default.
• W3029128617 creator A5020748223 @default.
• W3029128617 creator A5040694387 @default.
• W3029128617 date "2012-08-15" @default.
• W3029128617 modified "2023-09-23" @default.
• W3029128617 title "The clinical efficacy of mesalazine and bifid-triple viable combination therapy in patients with ulcerative colitis" @default.
• W3029128617 doi "https://doi.org/10.3760/cma.j.issn.0254-1432.2012.08.005" @default.
• W3029128617 hasPublicationYear "2012" @default.
• W3029128617 type Work @default.
• W3029128617 sameAs 3029128617 @default.
• W3029128617 citedByCount "0" @default.
• W3029128617 crossrefType "journal-article" @default.
• W3029128617 hasAuthorship W3029128617A5016101082 @default.
• W3029128617 hasAuthorship W3029128617A5020748223 @default.
• W3029128617 hasAuthorship W3029128617A5040694387 @default.
• W3029128617 hasConcept C126322002 @default.
• W3029128617 hasConcept C2775862500 @default.
• W3029128617 hasConcept C2776151105 @default.
• W3029128617 hasConcept C2778401633 @default.
• W3029128617 hasConcept C2779134260 @default.
• W3029128617 hasConcept C2779174533 @default.
• W3029128617 hasConcept C2780479503 @default.
• W3029128617 hasConcept C71924100 @default.
• W3029128617 hasConcept C90924648 @default.
• W3029128617 hasConceptScore W3029128617C126322002 @default.
• W3029128617 hasConceptScore W3029128617C2775862500 @default.
• W3029128617 hasConceptScore W3029128617C2776151105 @default.
• W3029128617 hasConceptScore W3029128617C2778401633 @default.
• W3029128617 hasConceptScore W3029128617C2779134260 @default.
• W3029128617 hasConceptScore W3029128617C2779174533 @default.
• W3029128617 hasConceptScore W3029128617C2780479503 @default.
• W3029128617 hasConceptScore W3029128617C71924100 @default.
• W3029128617 hasConceptScore W3029128617C90924648 @default.
• W3029128617 hasIssue "08" @default.
• W3029128617 hasLocation W30291286171 @default.
• W3029128617 hasOpenAccess W3029128617 @default.
• W3029128617 hasPrimaryLocation W30291286171 @default.
• W3029128617 hasRelatedWork W2348274487 @default.
• W3029128617 hasRelatedWork W2359387949 @default.
• W3029128617 hasRelatedWork W2362722411 @default.
• W3029128617 hasRelatedWork W2369622423 @default.
• W3029128617 hasRelatedWork W2372884731 @default.
• W3029128617 hasRelatedWork W2379234595 @default.
• W3029128617 hasRelatedWork W2382965758 @default.
• W3029128617 hasRelatedWork W2383717722 @default.
• W3029128617 hasRelatedWork W2384530364 @default.
• W3029128617 hasRelatedWork W2384830745 @default.
• W3029128617 hasRelatedWork W2385833234 @default.
• W3029128617 hasRelatedWork W2393725495 @default.
• W3029128617 hasRelatedWork W3028605810 @default.
• W3029128617 hasRelatedWork W3029562848 @default.
• W3029128617 hasRelatedWork W3029679773 @default.
• W3029128617 hasRelatedWork W3030153737 @default.
• W3029128617 hasRelatedWork W3030255663 @default.
• W3029128617 hasRelatedWork W3030992568 @default.
• W3029128617 hasRelatedWork W3031565937 @default.
• W3029128617 hasRelatedWork W3188684296 @default.
• W3029128617 hasVolume "32" @default.
• W3029128617 isParatext "false" @default.
• W3029128617 isRetracted "false" @default.
• W3029128617 magId "3029128617" @default.
• W3029128617 workType "article" @default.